Roivant Sciences Ltd annual operating income for fiscal TTM was -$1.4 billion, a decrease of 6.4% from -$1.3 billion in fiscal 2026. All figures are reported results from public filings — no estimates or projections.
| Operating Income (annual) | TTM → 2026-06-30 | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Income (EBIT) | ($1.4B) | ($1.3B) | ($1.1B) | ($825M) | ($809M) | ($1.2B) | ($1.1B) | ($532M) | ($748M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Operating Income (quarterly) | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Income (EBIT) | ($366M) | ($355M) | ($339M) | ($306M) | ($285M) | ($285M) | ($274M) | ($342M) | ($342M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
More ROIV metrics: Revenue · Gross Profit · Net Income · EPS · EBITDA · Free Cash Flow · Shares Outstanding
All ROIV financial statements → Interactive ROIV charts →
About TickerBase · Data methodology & sources · Privacy · Terms